利拉鲁肽在2型糖尿病并冠心病老年患者中的应用效果及对TNF-α、CRP水平的影响

Application effect of liraglutide in elderly patients with type 2 diabetes mellitus and coronary heart disease and its influences on TNF-αand CRP levels

目的分析利拉鲁肽在2型糖尿病(T2DM)并冠心病(CHD)老年患者中的应用效果。方法选取2020年1月至2022年12月收治的90例T2DM并CHD老年患者作为研究对象,以治疗方案差异将其分为对照组(n=45,常规综合疗法)和研究组(n=45,在对照组用药基础上联合利拉鲁肽治疗)。比较两组的血糖、血脂、心功能指标、炎性与血管内皮因子及临床疗效。结果治疗后,研究组的空腹血糖(FBG)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平低于对照组,左心室射血分数(LVEF)、舒张早期/舒张晚期二尖瓣血流速度比值(E/A)高于对照组(P<0.05)。治疗后,研究组的肿瘤坏死因子-α(TNF-α)、C-反应蛋白(CRP)、甲壳质酶蛋白-40(YKL-40)水平低于对照组,过氧化物酶体增殖物激活受体γ(PPARγ)、内脏脂肪组织特异性丝氨酸蛋白酶抑制因子(Vaspin)、Ghrelin水平高于对照组(P<0.05)。研究组的治疗总有效率显著高于对照组(P<0.05)。结论利拉鲁肽有助于调节T2DM并CHD老年患者的血糖、血脂及炎性与血管内皮细胞因子水平,改善心功能,值得在临床推广及应用。

Objective To analyze the application effect of liraglutide in elderly patients with type 2 diabetes mellitus(T2DM)and coronary heart disease(CHD).Methods A total of 90 elderly patients with T2DM and CHD admitted from January 2020 to December 2022 were selected as the research objects.According to the difference of treatment plan,and the patients were divided into control group(n=45,routine comprehensive therapy)and study group(n=45,combined with liraglutide treatment on the basis of the control group).The blood glucose,blood lipid and cardiac function indexes,inflammatory and vascular endothelial factors and clinical efficacy were compared between the two groups.Results After treatment,the fasting blood glucose(FBG),glycosylated hemoglobin(HbA1c),total cholesterol(TC)and low-density lipoprotein cholesterol(LDL-C)levels in the study group were lower than those in the control group,and left ventricular ejection fraction(LVEF)and early/late diastolic mitral flow velocity ratio(E/A)were higher than those in the control group(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),C-reactive protein(CRP)and chitinase protein 40(YKL-40)in the study group were lower than those in the control group,and the levels of peroxisome proliferators activated receptorγ(PPARγ),visceral adipose tissue-derived serine protease inhibitor(Vaspin)and Ghrelin were higher than those in the control group(P<0.05).The total effective rate of treatment in the study group was significantly higher than that in the control group(P<0.05).Conclusion Liraglutide is beneficial to regulate the levels of blood glucose,blood lipids and inflammatory and vascular endothelial factors in elderly patients with T2DM and CHD,and improve cardiac function,it is worthy of clinical promotion and application.